Professor Donghyun Kim of the Department of Ophthalmology at 高丽大学安岩医院 demonstrated the therapeutic 疗效 of a new 炎症 眼部 disease treatment, RCI001, in 干燥综合征.
干燥综合征 is an autoimmune disease characterized by chronic 炎症 of the salivary and lacrimal glands, resulting in dry mouth and 干眼.
It primarily occurs in the elderly, and as there is currently no fundamental cure, only symptomatic treatments are used.
To treat 干眼 caused by 干燥综合征, 抗炎 agents such as artificial tears, topical corticosteroids, cyclosporin A, and lifitegrast are used, but they have limited effectiveness or poor 眼部 comfort upon 滴眼.
In particular, steroids carry risks of 眼内压升高 and cataracts with long-term use, while cyclosporin A and lifitegrast are known to cause 灼热 and 刺痛 upon 滴眼. Therefore, there is a need for new treatments with excellent 抗炎 effects and favorable 眼部 comfort.
RCI001, jointly developed by RudaCure and 翰林制药, is a novel topical 滴眼液 formulation that has been confirmed to have simultaneous 抗炎 and 抗氧化 activity through TRPV1 下游信号调控.
In this study, a 干燥综合征 model was established by injecting botulinum toxin into the lacrimal glands of mice, and RCI001 was administered topically for 14 days to evaluate its effects. The results showed significant improvement in 泪液量, 角膜上皮 damage, and conjunctival goblet cell density.
Professor Kim stated, "RCI001 demonstrates meaningful therapeutic potential not only for general 干眼症 but also for autoimmune-related 干眼 such as 干燥综合征, and further clinical development is anticipated."
